Related Announcements

RFA-FD-22-013 - Development of Advanced Analytical Methods for Analyzing Diastereomer Compositions in Oligonucleotides (U01) Clinical Trial Not Allowed

Issued by

U.S. Food and Drug Administration (FDA)

Purpose

This notice is to extend the Application and Letter of Intent Due Dates for RFA-FD-22-013 - "Development of Advanced Analytical Methods for Analyzing Diastereomer Compositions in Oligonucleotides (U01) Clinical Trial Not Allowed"

New Letter of Intent Due Date

February 7, 2022

New Application Due Date(s)

March 7, 2022 by 11:59 PM Eastern Time

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the applications during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Late applications will not be acceptable for this FOA.
 

Inquiries

Please direct all inquiries to:

Shashi Malhotra

Grants Management Specialist

Office if Acqusitions and Grants Services

Tel: 240-402-7592

Email: Shashi.Malhotra@fda.hhs.gov